SHH · 603538.SS
Ningbo Menovo Pharmaceutical Co., Ltd.
CN¥20.90+CN¥0.62 (+3.06%)
Ningbo Menovo Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.43% below the high.
Loading market information…
SHZ · 002688.SZ · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Jinhe Biotechnology Co. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 35.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Jinhe Biotechnology Co. Ltd.’s forward annual dividend is CN¥0.10 per share, paid annual. The forward yield is 2.2% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Jinhe Biotechnology Co. Ltd.’s next earnings report is currently expected on Oct 30, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jinhe Biotechnology Co. Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Founded in 1990 and headquartered in Dalian, China, Jinhe Biotechnology Co. Ltd. focuses on the development and distribution of animal health pharmaceuticals both domestically and internationally. The company provides chlortetracycline in a feed-grade formulation, an antimicrobial compound vital for preventing and treating conditions like white dysentery, enteritis, pneumonia, typhoid, paratyphoid, and cholera in poultry and livestock. Additionally, its offerings include chlortetracycline hydrochloride, utilized to combat pullorum disease, typhoid, swine enteritis, and other bacterial ailments such as paratyphoid and cholera. Jinhe Biotechnology extends its market reach globally, exporting these veterinary solutions to regions including the United States, Southeast Asia, Latin America, and Europe.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:21 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥20.90+CN¥0.62 (+3.06%)
Ningbo Menovo Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.43% below the high.
CN¥10.44+CN¥0.20 (+1.95%)
ZhuZhou QianJin Pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 31.54% below the high.
CN¥7.16+CN¥0.06 (+0.85%)
Yabao Pharmaceutical Group Co., Ltd’s quoted price sits in the upper half of its reported 52-week range, 3.89% below the high.
CN¥8.42-CN¥0.14 (-1.64%)
HPGC Renmintongtai Pharmaceutical Corporation’s quoted price sits in the lower half of its reported 52-week range, 53.56% below the high.
CN¥3.56+CN¥0.01 (+0.28%)
Fuan Pharmaceutical (Group) Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.8% below the high.
CN¥7.37-CN¥0.04 (-0.54%)
LanZhou Foci Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.12% below the high.
CN¥8.37CN¥0.00 (0.0%)
Tibet Weixinkang Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.55% below the high.
CN¥7.94-CN¥0.08 (-1.0%)
Zhejiang Starry Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 44.75% below the high.
